RT Journal Article
SR Electronic
T1 Alcohol Use Disorder-Associated DNA Methylation in the Nucleus Accumbens and Dorsolateral Prefrontal Cortex
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.17.23300238
DO 10.1101/2024.01.17.23300238
A1 White, Julie D.
A1 Minto, Melyssa S.
A1 Willis, Caryn
A1 Quach, Bryan C.
A1 Han, Shizhong
A1 Tao, Ran
A1 Deep-Soboslay, Amy
A1 Zillich, Lea
A1 Clark, Shaunna L.
A1 van den Oord, Edwin J. C. G.
A1 Hyde, Thomas M.
A1 Mayfield, R. Dayne
A1 Webb, Bradley T.
A1 Johnson, Eric O.
A1 Kleinman, Joel E.
A1 Bierut, Laura J.
A1 Hancock, Dana B.
YR 2024
UL http://medrxiv.org/content/early/2024/01/17/2024.01.17.23300238.abstract
AB Background Alcohol use disorder (AUD) has a profound public health impact. However, understanding of the molecular mechanisms underlying the development and progression of AUD remain limited. Here, we interrogate AUD-associated DNA methylation (DNAm) changes within and across addiction-relevant brain regions: the nucleus accumbens (NAc) and dorsolateral prefrontal cortex (DLPFC).Methods Illumina HumanMethylation EPIC array data from 119 decedents of European ancestry (61 cases, 58 controls) were analyzed using robust linear regression, with adjustment for technical and biological variables. Associations were characterized using integrative analyses of public gene regulatory data and published genetic and epigenetic studies. We additionally tested for brain region-shared and -specific associations using mixed effects modeling and assessed implications of these results using public gene expression data.Results At a false discovery rate ≤ 0.05, we identified 53 CpGs significantly associated with AUD status for NAc and 31 CpGs for DLPFC. In a meta-analysis across the regions, we identified an additional 21 CpGs associated with AUD, for a total of 105 unique AUD-associated CpGs (120 genes). AUD-associated CpGs were enriched in histone marks that tag active promoters and our strongest signals were specific to a single brain region. Of the 120 genes, 23 overlapped with previous genetic associations for substance use behaviors; all others represent novel associations.Conclusions Our findings identify AUD-associated methylation signals, the majority of which are specific within NAc or DLPFC. Some signals may constitute predisposing genetic and epigenetic variation, though more work is needed to further disentangle the neurobiological gene regulatory differences associated with AUD.Competing Interest StatementThe following authors declare no conflict of interest: JDW, MSM, CW, BCQ, SH, RT, AD-S, LZ, SLC, EJCGvdO, TMH, RDM, BTW, EOJ, and DBH. JEK is a member of a drug monitoring committee for an antipsychotic drug trial for Merck. LBJ is listed as an inventor on U.S. Patent 8,080,371, 'Markers for Addiction' covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction.Funding StatementThis work was supported by the National Institute on Alcohol Abuse and Alcoholism R01 AA027049 (mPI: Hancock & Bierut)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB committee of RTI International waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes